Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| MCF 10A | Alvocidib | 1.0 | 0.99337 | |
| MCF7 | MK 1775 | 1.0 | 0.98664 | |
| MCF7 | MK 1775 | 10.0 | 0.98664 | |
| MCF7 | Alvocidib | 0.316227766 | 0.98664 | |
| MCF7 | MK 1775 | 3.16227766 | 0.98664 | |
| CAL-120 | Alvocidib | 0.316227766017 | 0.98534 | |
| CAL-120 | THZ1 | 0.316227766017 | 0.98534 | |
| CAL-120 | THZ1 | 0.316227766017 | 0.98534 | |
| HCC1806 | BMS-265246 | 3.16227766 | 0.98083 | |
| HCC1806 | THZ1 | 0.316227766 | 0.98083 | |
| T47D | Ribociclib | 0.031622777 | 0.97867 | |
| HCC1419 | AZD6738 | 10.0 | 0.96465 | |
| HCC1419 | LY3023414 | 0.001 | 0.96465 | |
| SK-BR-3 | AZD6738 | 10.0 | 0.96172 | |
| SK-BR-3 | BMS-265246 | 10.0 | 0.96172 | |
| BT-549 | RO-3306 | 10.0 | 0.95612 | |
| MDA-MB-436 | AZD6738 | 10.0 | 0.94793 | |
| HCC70 | THZ1 | 0.1 | 0.94621 | |
| MCF 10A | Alvocidib | 1.0 | -0.7589 | 0.94138 |
| HCC1954 | BMS-265246 | 0.1 | 0.93686 | |
| HME1 | THZ1 | 1.0 | 0.93226 | |
| MDA-MB-134-VI | Ulixertinib | 1.0 | 0.91225 | |
| MDA-MB-134-VI | Alvocidib | 0.316227766017 | 0.91225 | |
| MDA-MB-134-VI | BMS-265246 | 3.16227766017 | 0.91225 | |
| MDA-MB-134-VI | Ulixertinib | 0.003162278 | 0.91225 |